Drugs Made In America Acquisition market cap DMAA
Share price times shares outstanding: what the whole company sells for, since 2025.
- Today, Nov 2, 2026
- $264.3M
- Highest close in our data
- $357.4M
- May 2026
Drugs Made In America Acquisition is worth $264.3M at the close on Nov 2, 2026, at $10.89 a share.
That is down 24% over the last year.
Its highest close in our data was $357.4M in May 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $264.3M | $257.1M | $357.4M | −24% |
| 2025 | $347.6M | $335.8M | $347.6M | n/a |
Against its peers
Companies in Financial Services nearest Drugs Made In America Acquisition's size, closest first, today.
| Company | Market cap |
|---|---|
| DMAADrugs Made In America Acquisition | $264.3M |
| RMBIRichmond Mutual Bancorporation | $264.6M |
| NKSHNational Bankshares | $261M |
| HWBKHawthorn Bancshares | $271.5M |
| SNFCASecurity National Financial | $254.1M |
| POWWOutdoor | $279.6M |
| EFSIEagle Financial Services | $248.6M |
| WNEBWestern New England Bancorp | $281.8M |
| FXNCFirst National | $283.6M |
| LCNBLCNB | $285.1M |
| VABKVirginia National Bankshares | $286.5M |
| Peer median | $275.5M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Drugs Made In America Acquisition
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.